Sotera Health Company — Form 8-K Summary
Business Context and Reporting Period
Sotera Health Company filed a Form 8-K on June 1, 2023, reporting the results of its 2023 Annual Meeting of Shareholders held May 25, 2023. The meeting covered matters described in the definitive proxy statement filed April 13, 2023. The March 31, 2023 record date determined shareholder voting eligibility.
- 269,925,525 shares were represented in person or by proxy, equal to 95.54% of voting power.
- A quorum was present.
- The company’s common stock trades on Nasdaq under the symbol SHC.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics. It is limited to shareholder voting results.
Material Changes Versus the Prior Comparable Period
The filing does not provide a prior-period comparison or identify changes in financial performance or operations.
Meeting Results, Outlook, and Risks
- Director elections: Sean L. Cunningham, Robert B. Knauss, and Vincent K. Petrella were each elected as Class III directors for a three-year term ending at the 2026 annual meeting, subject to the election and qualification of successors.
- Executive compensation: Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers. The vote was 229,154,947 for, 38,382,040 against, and 112,899 abstaining, with 2,275,639 broker non-votes.
- Independent auditor: Shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 269,320,023 for, 504,464 against, and 101,038 abstaining; there were no broker non-votes.
- No financial guidance, management outlook, contingencies, unusual items, or new operating risks were disclosed in the filing.
Important Facts to Verify
- Confirm the three elected directors’ continued service and committee assignments in subsequent filings.
- Review the company’s proxy statement for detailed executive compensation matters underlying the advisory vote.
- Verify Ernst & Young LLP’s appointment and any subsequent auditor changes or audit-related disclosures.
- Consult the company’s periodic reports for financial performance, liquidity, debt, litigation, and other risk information not addressed in this 8-K.